Virginia Kaklamani

3 weeks ago | curetoday.com | Virginia Kaklamani |Megan Kruse

Author(s): , Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant Clinical Brief: Implementation and Patient Support Strategies Main Discussion Topics: Role of multidisciplinary care team in patient education and support Importance of early intervention for side effect management Strategies for ensuring medication adherence with oral therapy Value of...

3 weeks ago | businessandamerica.com | Virginia Kaklamani

Clinical Brief: Real-World Evidence Supporting Elacestrant Use Main Discussion Topics: Real-world outcomes exceeding clinical trial results (unusual finding) GUARDIAN database analysis: 6.4 months median time to treatment failure Komoda database: 6.8 months progression-free survival (9.4 months if fulvestrant-naive) Expert clinical experience aligning with real-world data Importance of appropriate patient selection for optimal outcomes Key Points for Physicians: Real-world PFS (6.4-6.8...

4 weeks ago | businessandamerica.com | Virginia Kaklamani

Clinical Brief: Elacestrant Subgroup Benefits and Safety Profile Main Discussion Topics: Efficacy across different disease sites (bone-only versus visceral) Impact of tumor burden (multiple sites of metastasis) Co-mutation status (PIK3CA, p53) and treatment efficacy Safety profile focusing on gastrointestinal (GI) tolerability and lipid monitoring FDA recommendation for lipid profile monitoring requirements Key Points for Physicians: Elacestrant efficacy maintained in visceral disease and...

4 weeks ago | businessandamerica.com | Virginia Kaklamani

Clinical Brief: Second-Line Treatment Decision Framework Main Discussion Topics: Integration of patient factors in treatment selection Balance between efficacy and quality-of-life considerations Practical considerations: insurance, copays, administration route Sequential versus concurrent treatment strategies Role of shared decision-making in complex treatment landscape Key Points for Physicians: Treatment selection requires balance of clinical trial data with patient-specific factors...

1 month ago | curetoday.com | Virginia Kaklamani |Megan Kruse

Author(s):,Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting.